ACB
Price
$3.90
Change
-$0.13 (-3.23%)
Updated
Sep 30 closing price
Capitalization
258.5M
41 days until earnings call
Intraday BUY SELL Signals
ALVO
Price
$5.80
Change
-$0.12 (-2.03%)
Updated
Sep 30 closing price
Capitalization
2.19B
41 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACB vs ALVO

ACB vs ALVO Comparison Chart in %
View a ticker or compare two or three
VS
ACB vs. ALVO commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Buy and ALVO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ACB vs ALVO: Fundamental Ratings
ACB
ALVO
OUTLOOK RATING
1..100
9093
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4236
P/E GROWTH RATING
1..100
8512
SEASONALITY SCORE
1..100
3075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (49) in the Pharmaceuticals Other industry is in the same range as ALVO (55) in the null industry. This means that ACB’s stock grew similarly to ALVO’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ALVO (100) in the null industry. This means that ACB’s stock grew similarly to ALVO’s over the last 12 months.

ACB's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as ALVO (100) in the null industry. This means that ACB’s stock grew similarly to ALVO’s over the last 12 months.

ALVO's Price Growth Rating (36) in the null industry is in the same range as ACB (42) in the Pharmaceuticals Other industry. This means that ALVO’s stock grew similarly to ACB’s over the last 12 months.

ALVO's P/E Growth Rating (12) in the null industry is significantly better than the same rating for ACB (85) in the Pharmaceuticals Other industry. This means that ALVO’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBALVO
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
65%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
62%
Advances
ODDS (%)
Bullish Trend 9 days ago
76%
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
66%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (ACB: $3.90 vs. ALVO: $5.80)
Brand notoriety: ACB: Notable vs. ALVO: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 110% vs. ALVO: 58%
Market capitalization -- ACB: $258.5M vs. ALVO: $2.19B
ACB [@Pharmaceuticals: Generic] is valued at $258.5M. ALVO’s [@Pharmaceuticals: Generic] market capitalization is $2.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green while ALVO’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • ALVO’s FA Score: 1 green, 4 red.
According to our system of comparison, ALVO is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while ALVO’s TA Score has 4 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 5 bearish.
  • ALVO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ACB and ALVO are a bad buy in the short-term.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -7.58% price change this week, while ALVO (@Pharmaceuticals: Generic) price change was -0.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.90%. For the same industry, the average monthly price growth was -4.53%, and the average quarterly price growth was +33.40%.

Reported Earning Dates

ACB is expected to report earnings on Nov 11, 2026.

ALVO is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.90% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ACB
Daily Signal:
Gain/Loss:
ALVO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SHYM21.380.17
+0.78%
iShares Short Duration High Yield Muni Active ETF (SHYM)
CAMX33.54N/A
N/A
Cambiar Aggressive Value ETF (CAMX)
DLLL32.62-0.12
-0.37%
GraniteShares 2x Long DELL Daily ETF (DLLL)
VTWO112.24-0.47
-0.42%
Vanguard Russell 2000 ETF (VTWO)
UST37.78-0.17
-0.44%
ProShares Ultra 7-10 Year Treasury (UST)

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-3.23%
CGC - ACB
78%
Closely correlated
-3.12%
TLRY - ACB
73%
Closely correlated
-5.06%
OGI - ACB
69%
Closely correlated
-6.93%
CRON - ACB
67%
Closely correlated
-2.37%
SNDL - ACB
65%
Loosely correlated
-5.15%
More

ALVO and

Correlation & Price change

A.I.dvisor tells us that ALVO and CRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and CRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALVO
1D Price
Change %
ALVO100%
-2.03%
CRON - ALVO
24%
Poorly correlated
-2.37%
EBS - ALVO
23%
Poorly correlated
-4.62%
PAHC - ALVO
22%
Poorly correlated
+0.82%
ACB - ALVO
22%
Poorly correlated
-3.23%
LFCR - ALVO
21%
Poorly correlated
-0.15%
More